- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01006551
Ziprasidone in Early Onset Schizophrenia Spectrum Disorders (ZEOSS)
November 2, 2009 updated by: University of North Carolina, Chapel Hill
This is an open trial of ziprasidone (ZIP) in children and adolescents.
It is designed to provide pilot data on the magnitude of ZIP's antipsychotic effects in psychotic youth, dosing ranges, acute safety, and tolerability.
This would then inform the design of a rigorous, randomized controlled trial of ZIP in the pediatric population.
The primary study hypothesis is that the proportion of pediatric subjects responding to treatment with ziprasidone will be comparable or greater than reported in trials of ziprasidone in adults.
Study Overview
Detailed Description
The study will consist of two phases: an eight week acute phase and a 44 week continuation phase for those subjects who show a response during the first eight weeks.
All treatment will be open label and monitored by research clinicians with expertise in treating psychotic youth.
The initial titration is relatively slow to minimize side effects.
A flexible dose strategy in which each individual's ultimate dose is determined by his/her response and side effects will be used.
The maximal dose will be 160mg split as a BID dose.
We estimate that the average dose will be 120mg/d.
Concurrent use of benztropine, propranolol, and benzodiazepines (lorazepam and clonazepam) will be permitted as needed to treat any emergent extrapyramidal side effects and agitation.
Concurrent use of antidepressants and mood stabilizers will be permitted in those subjects who have been on stable doses of antidepressants or mood stabilizers for at least four weeks at time of entry, or those with emergence of significant affective symptoms during the maintenance phase of the study.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Medford, Massachusetts, United States, 02155
- Harvard University
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina, Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
-
Washington
-
Seattle, Washington, United States, 98125
- University of Washington
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 19 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Between 6 and 19 years old, male or female.
- Significant psychotic symptoms defined by a behavior score of at least 4 (moderate) on at least one of the psychotic items of Positive and Negative Symptom Scale (PANSS) at baseline.
- Subjects will meet DSM IV criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder.
- Subjects will be free of depot antipsychotic medication for at least six months.
- Good physical health.
- The subject gives informed assent for the study and his/her guardian is able and willing to give informed consent.
- Mood stabilizing treatment (i.e., antidepressant, lithium, carbamazepine, valproate) will be permitted during the first eight weeks of the study only if the patient has been treated with the mood stabilizer for at least 30 days. Dosages will remain stable for the first 8 weeks unless change or discontinuation is clinically indicated.
Exclusion Criteria:
- A primary diagnosis of substance abuse or dependence.
- Known endocrinological or neurological conditions, which confound the diagnosis or are a contraindication to treatment with antipsychotics.
- Subjects with a clear history of intolerance or nonresponsiveness to ziprasidone.
- Subjects at serious, short term risk for suicide.
- Subjects who are pregnant or who refuse to practice contraception during the study.
- Subjects with known cardiac conduction problems especially prior QTc prolongation, known genetic risk for QTc prolongation or who are being treated with other agents that prolong the QTc. These agents include the antiarrhythmic agents: dofetilide (Tkosyn), sotalol (Betapace), quinidine (Quinaglute), or Class 1A and III antiarrhythmics; the antipsychotics mesoridazine (Serentil), thioridazine (Mellaril), chlorpromazine (Thorazine), droperidol (Inapsine), pimozide (Orap); the anti-infectives: sparfloxacin (Zagam), gatifloxacin (Tequin), moxifloxacin (Avelox), pentamidine (Pentam); the anti-malarials halofantrine (Halfan), mefloquine (Lariam); and arsenic trioxide (Trisenox), levomethadyl acetate (Orlaam), dolasetron mesylate (Anzemet), probucol (Lorelco-an antilipemic), and tacrolimus (Prograf).
- Subjects with a diagnosis of a pervasive developmental disorder or an autism screening questionnaire score >15, must have clear hallucinations or delusions.
- Subjects will be excluded if they meet criteria for a current major depressive episode.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ziprasidone
|
20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial.
In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome measure will be responder status, defined as a CGI improvement score of 1 or 2, plus a 20 % reduction in the baseline PANSS score at week 8.
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
A correlational analysis will be done to examine the potential relationship between dose and treatment response, and reduction in positive and negative symptoms.
Time Frame: 52 weeks
|
52 weeks
|
Subsequent analyses will examine the ZEOSS week 0 visit scores to assess for further improvement in symptoms and ability to sustain response/prevent relapse in subjects who responded to but could not tolerate the prior antipsychotic.
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Linmarie Sikich, MD, University of North Carolina, Chapel Hill
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2002
Primary Completion (Actual)
February 1, 2006
Study Completion (Actual)
February 1, 2006
Study Registration Dates
First Submitted
November 2, 2009
First Submitted That Met QC Criteria
November 2, 2009
First Posted (Estimate)
November 3, 2009
Study Record Updates
Last Update Posted (Estimate)
November 3, 2009
Last Update Submitted That Met QC Criteria
November 2, 2009
Last Verified
November 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Ziprasidone
Other Study ID Numbers
- 2002-0012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Ziprasidone
-
Donald C. Goff, MDPfizerCompletedSchizophreniaUnited States
-
Bronx Psychiatric CenterPfizer; Buffalo Psychiatric Center; Rochester Psychiatric CenterCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Yale UniversityCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Dr. Reddy's Laboratories LimitedCompletedHealthyUnited States
-
Fundació Institut de Recerca de l'Hospital de la...Pfizer; Ministry of Health, Spain; REM-TAP NetworkCompletedBorderline Personality DisorderSpain
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPsychotic Disorders | SchizophreniaTurkey, Egypt, Greece, Lebanon, Jordan, Kuwait, Saudi Arabia, South Africa, United Arab Emirates
-
Tufts Medical CenterPfizerCompletedDepression | Bipolar Disorder | Bipolar DepressionUnited States
-
Central Institute of Mental Health, MannheimCompletedSchizophrenia, Schizoaffective DisorderGermany